| Updated on March 14, 2018 Published on December 05, 2017

we hereby intimate you that SHILPA MEDICARE LIMITED has received 483 Observations from the United States Food & Drug Administration (USFDA) in relation to SEZ Formulation Facilities situated at Jadcherla, Telangana (near Hyderabad) as under;

a) Total 10 observations were cited during the close up meeting.
b) 7 observations are improvement in procedures and practices.
c) 3 observations are related to setting of analytical specifications, test procedures and method validation.

This is for your information and doing the needful

Pdf Link: Updates

Source : BSE - www.bseindia.com

Published on December 05, 2017
This article is closed for comments.
Please Email the Editor